{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:17:35Z","timestamp":1788308255916,"version":"build-2803163510"},"reference-count":70,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Meningioma risk stratification has historically been defined by the Simpson grade of resection and the histological grade of tumor tissue. Recent scientific advances have elucidated the molecular architecture of meningioma, and multiple groups have developed molecular classification systems that refine meningioma risk stratification. Reported meningioma molecular classification systems use DNA methylation or gene expression profiling, copy number alterations, DNA mutations, or multiple molecular and histological variables combined into individual models. While the details of meningioma molecular classification systems may vary, concordance is observed across unsupervised systems that are not trained on clinical outcomes, suggesting conserved tumor biology. Moreover, some molecular classification systems outperform the WHO grade in risk stratification and can identify meningiomas that may benefit from radiotherapy or targeted therapies. According to this emerging paradigm, patients with molecular high-risk meningioma may be guided toward postoperative radiotherapy or targeted therapies. In contrast, patients with molecular low-risk meningioma may be followed with serial postoperative imaging in the right clinical context. Practical and logistical barriers must be overcome to implement meningioma molecular classification into clinical practice, and prospective randomized trials are needed to validate emerging molecular risk stratification systems and define the subsets of patients who might benefit the most from their use. In the interim, clinicians are increasingly recognizing the value of meningioma molecular classification and are already implementing these approaches into the postoperative management of patients with meningioma.<\/jats:p>","DOI":"10.3171\/2026.6.focus26255","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:01:23Z","timestamp":1787702483000},"page":"E10","source":"Crossref","is-referenced-by-count":0,"title":["Integrating molecular classification into postoperative intracranial meningioma management"],"prefix":"10.3171","volume":"61","author":[{"given":"Brooke C.","family":"Braman","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of California, San Francisco;"},{"name":"Department of Neurological Surgery, University of California, San Francisco; and"},{"name":"Department of Pathology, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, San Francisco;"},{"name":"Department of Neurological Surgery, University of California, San Francisco; and"},{"name":"Department of Pathology, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"Supplement_4","key":"b1","series-title":"Neuro Oncol","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022","volume":"27","author":"Price M","year":"2025","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022. Neuro Oncol. 2025;27(Supplement_4):iv1\u2013iv66. doi:10.1093\/neuonc\/noaf194"},{"issue":"1","key":"b2","series-title":"J Neurol Neurosurg Psychiatry","first-page":"22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson D","year":"1957","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339. doi:10.1136\/jnnp.20.1.22"},{"issue":"3","key":"b3","series-title":"J Neurosurg","first-page":"551","article-title":"The Simpson grading revisited: aggressive surgery and its place in modern meningioma management","volume":"125","author":"Gousias K","year":"2016","unstructured":"Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg. 2016;125(3):551\u2013560. doi:10.3171\/2015.9.JNS15754"},{"issue":"2","key":"b4","series-title":"J Neurosurg","first-page":"515","article-title":"Prognostic value of the Simpson grading scale in modern meningioma surgery: Barrow Neurological Institute experience","volume":"135","author":"Przybylowski CJ","year":"2021","unstructured":"Przybylowski CJ, Hendricks BK, Frisoli FA,  Prognostic value of the Simpson grading scale in modern meningioma surgery: Barrow Neurological Institute experience. J Neurosurg. 2021;135(2):515\u2013523. doi:10.3171\/2020.6.JNS20374"},{"issue":"2","key":"b5","series-title":"J Neurosurg","first-page":"488","article-title":"The Simpson grade: abandon the scale but preserve the message","volume":"135","author":"Schwartz TH","year":"2021","unstructured":"Schwartz TH, McDermott MW. The Simpson grade: abandon the scale but preserve the message. J Neurosurg. 2021;135(2):488\u2013495. doi:10.3171\/2020.6.JNS201904"},{"issue":"2","key":"b6","series-title":"Neurosurgery","first-page":"310","article-title":"The impact of MRI-defined extent of resection across meningioma DNA Methylation groups: re-evaluating surgery in the era of meningioma molecular classification","volume":"97","author":"Morshed RA","year":"2025","unstructured":"Morshed RA, Nguyen MP, Choudhury A,  The impact of MRI-defined extent of resection across meningioma DNA Methylation groups: re-evaluating surgery in the era of meningioma molecular classification. Neurosurgery. 2025;97(2):310\u2013319. doi:10.1227\/neu.0000000000003324"},{"issue":"5","key":"b7","series-title":"J Neuroimaging","first-page":"650","article-title":"Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas","volume":"29","author":"Ivanidze J","year":"2019","unstructured":"Ivanidze J, Roytman M, Lin E,  Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging. 2019;29(5):650\u2013656. doi:10.1111\/jon.12632"},{"issue":"3","key":"b8","series-title":"J Nucl Med","first-page":"347","article-title":"Increased68 Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger W","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA,  Increased68 Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347\u2013353. doi:10.2967\/jnumed.114.149120"},{"issue":"3-4","key":"b9","series-title":"Cytogenet Cell Genet","first-page":"207","article-title":"Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases","volume":"93","author":"Zang KD","year":"2001","unstructured":"Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet. 2001;93(3-4):207\u2013220. doi:10.1159\/000056986"},{"issue":"6123","key":"b10","series-title":"Science","first-page":"1077","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark VE","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A,  Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077\u20131080. doi:10.1126\/science.1233009"},{"issue":"5","key":"b11","series-title":"J Neurosurg","first-page":"1345","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood MW","year":"2020","unstructured":"Youngblood MW, Duran D, Montejo JD,  Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg. 2020;133(5):1345\u20131354. doi:10.3171\/2019.8.JNS191266"},{"issue":"3","key":"b12","series-title":"Nat Genet","first-page":"285","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos PK","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S,  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285\u2013289. doi:10.1038\/ng.2526"},{"issue":"5","key":"b13","series-title":"J Natl Cancer Inst","first-page":"djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm F","year":"2016","unstructured":"Sahm F, Schrimpf D, Olar A,  TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):djv377. doi:10.1093\/jnci\/djv377"},{"issue":"2","key":"b14","series-title":"Cancer Genet Cytogenet","first-page":"103","article-title":"Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas","volume":"110","author":"Lamszus K","year":"1999","unstructured":"Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet. 1999;110(2):103\u2013110. doi:10.1016\/s0165-4608(98)00209-x"},{"issue":"2","key":"b15","series-title":"J Neurooncol","first-page":"167","article-title":"Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma","volume":"41","author":"Ozaki S","year":"1999","unstructured":"Ozaki S, Nishizaki T, Ito H, Sasaki K. Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol. 1999;41(2):167\u2013174. doi:10.1023\/a:1006086723607"},{"issue":"1","key":"b16","series-title":"Cancer Genet Cytogenet","first-page":"30","article-title":"High-resolution analysis of chromosome arm 1p alterations in meningioma","volume":"120","author":"Bello MJ","year":"2000","unstructured":"Bello MJ, De Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet. 2000;120(1):30\u201336. doi:10.1016\/s0165-4608(99)00249-6"},{"issue":"1","key":"b17","series-title":"Nat Commun","first-page":"14433","article-title":"Integrated genomic analyses of de novo pathways underlying atypical meningiomas","volume":"8","author":"Harmanc\u0131 AS","year":"2017","unstructured":"Harmanc\u0131 AS, Youngblood MW, Clark VE,  Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017;8(1):14433. doi:10.1038\/ncomms14433"},{"issue":"2","key":"b18","series-title":"Neuro Oncol","first-page":"319","article-title":"cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm F","year":"2025","unstructured":"Sahm F, Aldape KD, Brastianos PK,  cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 2025;27(2):319\u2013330. doi:10.1093\/neuonc\/noae170"},{"issue":"Suppl 1","key":"b19","series-title":"Neuro Oncol","first-page":"i18","article-title":"Advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos PK","year":"2019","unstructured":"Brastianos PK, Galanis E, Butowski N,  Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019;21(Suppl 1):i18\u2013i31. doi:10.1093\/neuonc\/noy136"},{"issue":"2","key":"b20","series-title":"Nat Rev Neurol","first-page":"106","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser M","year":"2018","unstructured":"Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol. 2018;14(2):106\u2013115. doi:10.1038\/nrneurol.2017.168"},{"issue":"8","key":"b21","series-title":"Neuro Oncol","first-page":"1231","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P,  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u20131251. doi:10.1093\/neuonc\/noab106"},{"issue":"11","key":"b22","series-title":"Neuro Oncol","first-page":"1821","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner R","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD,  EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u20131834. doi:10.1093\/neuonc\/noab150"},{"issue":"10","key":"b23","series-title":"Neuro Oncol","first-page":"1742","article-title":"Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients","volume":"26","author":"Wang JZ","year":"2024","unstructured":"Wang JZ, Landry AP, Raleigh DR,  Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024;26(10):1742\u20131780. doi:10.1093\/neuonc\/noae082"},{"key":"b24","series-title":"Natl Compr Cancer Netw","article-title":"NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers Version 2.2025","author":"Nabors LB","unstructured":"Nabors LB, Horbinski C, Pinho MC,  NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers Version 2.2025. Natl Compr Cancer Netw. Accessed July 15, 2026. https:\/\/virtualtrials.org\/pdf2025\/cns.pdf"},{"issue":"12","key":"b25","series-title":"Lancet Neurol","first-page":"1045","article-title":"Histological classification and molecular genetics of meningiomas","volume":"5","author":"Riemenschneider MJ","year":"2006","unstructured":"Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5(12):1045\u20131054. doi:10.1016\/S1474-4422(06)70625-1"},{"issue":"5","key":"b26","series-title":"Neuro Oncol","first-page":"649","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi M","year":"2016","unstructured":"Abedalthagafi M, Bi WL, Aizer AA,  Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016;18(5):649\u2013655. doi:10.1093\/neuonc\/nov316"},{"issue":"10","key":"b27","series-title":"Nat Genet","first-page":"1253","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark VE","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H,  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016;48(10):1253\u20131259. doi:10.1038\/ng.3651"},{"issue":"7","key":"b28","series-title":"Mod Pathol","first-page":"708","article-title":"Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system","volume":"29","author":"Yuzawa S","year":"2016","unstructured":"Yuzawa S, Nishihara H, Yamaguchi S,  Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Mod Pathol. 2016;29(7):708\u2013716. doi:10.1038\/modpathol.2016.81"},{"issue":"5","key":"b29","series-title":"Lancet Oncol","first-page":"682","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm F","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D,  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682\u2013694. doi:10.1016\/S1470-2045(17)30155-9"},{"issue":"7874","key":"b30","series-title":"Nature","first-page":"119","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri F","year":"2021","unstructured":"Nassiri F, Liu J, Patil V,  A clinically applicable integrative molecular classification of meningiomas. Nature. 2021;597(7874):119\u2013125. doi:10.1038\/s41586-021-03850-3"},{"issue":"5","key":"b31","series-title":"Neuro Oncol","first-page":"783","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood MW","year":"2021","unstructured":"Youngblood MW, Miyagishima DF, Jin L,  Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol. 2021;23(5):783\u2013794. doi:10.1093\/neuonc\/noaa226"},{"issue":"2","key":"b32","series-title":"Brain Pathol","first-page":"e12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff AS","year":"2022","unstructured":"Berghoff AS, Hielscher T, Ricken G,  Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathol. 2022;32(2):e12970. doi:10.1111\/bpa.12970"},{"issue":"3","key":"b33","series-title":"Acta Neuropathol","first-page":"409","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers P","year":"2020","unstructured":"Sievers P, Hielscher T, Schrimpf D,  CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020;140(3):409\u2013413. doi:10.1007\/s00401-020-02188-w"},{"issue":"4","key":"b34","series-title":"Acta Neuropathol","first-page":"501","article-title":"Even heterozygous loss of CDKN2A\/B greatly accelerates recurrence in aggressive meningioma","volume":"145","author":"Khan AB","year":"2023","unstructured":"Khan AB, English CW, Chen WC,  Even heterozygous loss of CDKN2A\/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023;145(4):501\u2013503. doi:10.1007\/s00401-023-02543-7"},{"issue":"1","key":"b35","series-title":"Acta Neuropathol","first-page":"145","article-title":"Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas","volume":"146","author":"Wang JZ","year":"2023","unstructured":"Wang JZ, Patil V, Liu J,  Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol. 2023;146(1):145\u2013162. doi:10.1007\/s00401-023-02571-3"},{"issue":"4","key":"b36","series-title":"Neuro Oncol","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar GM","year":"2017","unstructured":"Shankar GM, Abedalthagafi M, Vaubel RA,  Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017;19(4):535\u2013545. doi:10.1093\/neuonc\/now235"},{"issue":"2","key":"b37","series-title":"Acta Neuropathol","first-page":"281","article-title":"Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1","volume":"141","author":"Sievers P","year":"2021","unstructured":"Sievers P, Sill M, Blume C,  Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathol. 2021;141(2):281\u2013290. doi:10.1007\/s00401-020-02247-2"},{"issue":"5","key":"b38","series-title":"Acta Neuropathol","first-page":"779","article-title":"DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome","volume":"136","author":"Juratli TA","year":"2018","unstructured":"Juratli TA, McCabe D, Nayyar N,  DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779\u2013792. doi:10.1007\/s00401-018-1899-7"},{"issue":"5","key":"b39","series-title":"Nat Genet","first-page":"649","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury A","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD,  Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet. 2022;54(5):649\u2013659. doi:10.1038\/s41588-022-01061-8"},{"issue":"2","key":"b40","series-title":"Nat Med","first-page":"717","article-title":"Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial","volume":"32","author":"Brastianos PK","year":"2026","unstructured":"Brastianos PK, Dooley K, Geyer S,  Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. Nat Med. 2026;32(2):717\u2013724. doi:10.1038\/s41591-025-04141-4"},{"issue":"34","key":"b41","series-title":"J Clin Oncol","first-page":"3839","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas SLN","year":"2021","unstructured":"Maas SLN, Stichel D, Hielscher T,  Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J Clin Oncol. 2021;39(34):3839\u20133852. doi:10.1200\/JCO.21.00784"},{"issue":"5","key":"b42","series-title":"Neuro Oncol","first-page":"796","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver J","year":"2022","unstructured":"Driver J, Hoffman SE, Tavakol S,  A molecularly integrated grade for meningioma. Neuro Oncol. 2022;24(5):796\u2013808. doi:10.1093\/neuonc\/noab213"},{"issue":"5","key":"b43","series-title":"Neuro Oncol","first-page":"1258","article-title":"Development and validation of a molecular classifier of meningiomas","volume":"27","author":"Landry AP","year":"2025","unstructured":"Landry AP, Wang JZ, Liu J,  Development and validation of a molecular classifier of meningiomas. Neuro Oncol. 2025;27(5):1258\u20131269. doi:10.1093\/neuonc\/noae242"},{"issue":"1","key":"b44","series-title":"Nat Commun","first-page":"6025","article-title":"Distribution of copy number alterations and impact of chromosome arm call thresholds for meningioma","volume":"16","author":"Patel RV","year":"2025","unstructured":"Patel RV, Ghosh HS, Meredith DM,  Distribution of copy number alterations and impact of chromosome arm call thresholds for meningioma. Nat Commun. 2025;16(1):6025. doi:10.1038\/s41467-025-60734-0"},{"issue":"1","key":"b45","series-title":"Nat Commun","first-page":"6024","article-title":"Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification","volume":"16","author":"Nguyen MP","year":"2025","unstructured":"Nguyen MP, Chen WC, Mirchia K,  Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification. Nat Commun. 2025;16(1):6024. doi:10.1038\/s41467-025-61063-y"},{"issue":"6","key":"b46","series-title":"JAMA Oncol","first-page":"644","article-title":"Chromosome 1p loss and 1q gain for grading of meningioma","volume":"11","author":"Landry AP","year":"2025","unstructured":"Landry AP, Wang JZ, Patil V,  Chromosome 1p loss and 1q gain for grading of meningioma. JAMA Oncol. 2025;11(6):644\u2013649. doi:10.1001\/jamaoncol.2025.0329"},{"issue":"43","key":"b47","series-title":"Proc Natl Acad Sci U S A","first-page":"21715","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel AJ","year":"2019","unstructured":"Patel AJ, Wan YW, Al-Ouran R,  Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci U S A. 2019;116(43):21715\u201321726. doi:10.1073\/pnas.1912858116"},{"issue":"5","key":"b48","series-title":"Sci Adv","first-page":"eabm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley JC","year":"2022","unstructured":"Bayley JC, Hadley CC, Harmanci AO, Harmanci AS, Klisch TJ, Patel AJ. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv. 2022;8(5):eabm6247. doi:10.1126\/sciadv.abm6247"},{"issue":"6","key":"b49","series-title":"Acta Neuropathol","first-page":"837","article-title":"Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042\u201326042","volume":"146","author":"Maas SLN","year":"2023","unstructured":"Maas SLN, Sievers P, Weber DC,  Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042\u201326042. Acta Neuropathol. 2023;146(6):837\u2013840. doi:10.1007\/s00401-023-02642-5"},{"issue":"9","key":"b50","series-title":"Neuro Oncol","first-page":"2370","article-title":"Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-\/high-risk molecular profiles","volume":"27","author":"Deng MY","year":"2025","unstructured":"Deng MY, Maas SLN, Anil G,  Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-\/high-risk molecular profiles. Neuro Oncol. 2025;27(9):2370\u20132381. doi:10.1093\/neuonc\/noaf125"},{"issue":"3","key":"b51","series-title":"Neuro Oncol","first-page":"520","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury A","year":"2023","unstructured":"Choudhury A, Chen WC, Lucas CHG,  Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023;25(3):520\u2013530. doi:10.1093\/neuonc\/noac224"},{"issue":"6","key":"b52","series-title":"Nat Genet","first-page":"1121","article-title":"Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution","volume":"56","author":"Lucas CHG","year":"2024","unstructured":"Lucas CHG, Mirchia K, Seo K,  Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution. Nat Genet. 2024;56(6):1121\u20131133. doi:10.1038\/s41588-024-01747-1"},{"issue":"2","key":"b53","series-title":"Nat Genet","first-page":"341","article-title":"A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification","volume":"58","author":"Maas SLN","year":"2026","unstructured":"Maas SLN, Tang Y, Stutheit-Zhao E,  A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification. Nat Genet. 2026;58(2):341\u2013354. doi:10.1038\/s41588-025-02475-w"},{"issue":"1","key":"b54","series-title":"Nat Commun","first-page":"4803","article-title":"Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma","volume":"11","author":"Magill ST","year":"2020","unstructured":"Magill ST, Vasudevan HN, Seo K,  Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun. 2020;11(1):4803. doi:10.1038\/s41467-020-18582-7"},{"issue":"11","key":"b55","series-title":"Nat Med","first-page":"3173","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"30","author":"Wang JZ","year":"2024","unstructured":"Wang JZ, Patil V, Landry AP,  Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma. Nat Med. 2024;30(11):3173\u20133183. doi:10.1038\/s41591-024-03167-4"},{"issue":"13","key":"b56","series-title":"Cell Rep","first-page":"3672","article-title":"Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation","volume":"22","author":"Vasudevan HN","year":"2018","unstructured":"Vasudevan HN, Braunstein SE, Phillips JJ,  Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Rep. 2018;22(13):3672\u20133683. doi:10.1016\/j.celrep.2018.03.013"},{"issue":"12","key":"b57","series-title":"Nat Med","first-page":"3067","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen WC","year":"2023","unstructured":"Chen WC, Choudhury A, Youngblood MW,  Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023;29(12):3067\u20133076. doi:10.1038\/s41591-023-02586-z"},{"issue":"2","key":"b58","series-title":"Neuro Oncol","first-page":"445","article-title":"A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence","volume":"27","author":"Nguyen MP","year":"2025","unstructured":"Nguyen MP, Morshed RA, Youngblood MW,  A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro Oncol. 2025;27(2):445\u2013454. doi:10.1093\/neuonc\/noae198"},{"issue":"1","key":"b59","series-title":"Neuro Oncol","first-page":"137","article-title":"Low-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539","volume":"25","author":"Rogers CL","year":"2023","unstructured":"Rogers CL, Pugh SL, Vogelbaum MA,  Low-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539. Neuro Oncol. 2023;25(1):137\u2013145. doi:10.1093\/neuonc\/noac137"},{"issue":"3","key":"b60","series-title":"Neurosurgery","first-page":"521","article-title":"Gene expression changes associated with recurrence after gross total resection of newly diagnosed world health organization grade 1 meningioma","volume":"96","author":"Morshed RA","year":"2025","unstructured":"Morshed RA, Nguyen MP, Youngblood MW,  Gene expression changes associated with recurrence after gross total resection of newly diagnosed world health organization grade 1 meningioma. Neurosurgery. 2025;96(3):521\u2013528. doi:10.1227\/neu.0000000000003133"},{"issue":"Suppl 1","key":"b61","series-title":"Neurooncol Adv","first-page":"i67","article-title":"Radiotherapy and radiosurgery for meningiomas","volume":"5","author":"Chen WC","year":"2023","unstructured":"Chen WC, Lucas CHG, Magill ST, Rogers CL, Raleigh DR. Radiotherapy and radiosurgery for meningiomas. Neurooncol Adv. 2023;5(Suppl 1):i67\u2013i83. doi:10.1093\/noajnl\/vdac088"},{"issue":"1","key":"b62","series-title":"J Neurosurg","first-page":"35","article-title":"Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539","volume":"129","author":"Rogers L","year":"2018","unstructured":"Rogers L, Zhang P, Vogelbaum MA,  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129(1):35\u201347. doi:10.3171\/2016.11.JNS161170"},{"issue":"2","key":"b63","series-title":"Radiother Oncol","first-page":"260","article-title":"Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042-26042)","volume":"128","author":"Weber DC","year":"2018","unstructured":"Weber DC, Ares C, Villa S,  Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018;128(2):260\u2013265. doi:10.1016\/j.radonc.2018.06.018"},{"issue":"3","key":"b64","series-title":"Neurosurgery","first-page":"521","article-title":"The rationale for early adjuvant radiotherapy after gross total resection of atypical meningioma","volume":"97","author":"Raleigh DR","year":"2025","unstructured":"Raleigh DR, Leland Rogers C, Mehta MP,  The rationale for early adjuvant radiotherapy after gross total resection of atypical meningioma. Neurosurgery. 2025;97(3):521\u2013524. doi:10.1227\/neu.0000000000003624]"},{"issue":"1","key":"b65","series-title":"J Neurosurg","first-page":"4","article-title":"Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review","volume":"122","author":"Rogers L","year":"2015","unstructured":"Rogers L, Barani I, Chamberlain M,  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4\u201323. doi:10.3171\/2014.7.JNS131644"},{"issue":"4","key":"b66","series-title":"Int J Radiat Oncol Biol Phys","first-page":"790","article-title":"High-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539","volume":"106","author":"Rogers CL","year":"2020","unstructured":"Rogers CL, Won M, Vogelbaum MA,  High-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020;106(4):790\u2013799. doi:10.1016\/j.ijrobp.2019.11.028"},{"issue":"3","key":"b67","series-title":"Int J Radiat Oncol Biol Phys","first-page":"662","article-title":"Dose-escalated radiation therapy is associated with improved outcomes for high-grade meningioma","volume":"118","author":"Zeng KL","year":"2024","unstructured":"Zeng KL, Soliman H, Myrehaug S,  Dose-escalated radiation therapy is associated with improved outcomes for high-grade meningioma. Int J Radiat Oncol Biol Phys. 2024;118(3):662\u2013671. doi:10.1016\/j.ijrobp.2023.09.026"},{"issue":"4","key":"b68","series-title":"Neuro Oncol","first-page":"701","article-title":"Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial","volume":"26","author":"Deng MY","year":"2024","unstructured":"Deng MY, Maas SLN, Hinz F,  Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial. Neuro Oncol. 2024;26(4):701\u2013712. doi:10.1093\/neuonc\/noad244"},{"issue":"6","key":"b69","series-title":"Technol Cancer Res Treat","first-page":"607","article-title":"Dose escalation with proton radiation therapy for high-grade meningiomas","volume":"11","author":"Chan AW","year":"2012","unstructured":"Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS. Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat. 2012;11(6):607\u2013614. doi:10.7785\/tcrt.2012.500267"},{"issue":"1","key":"b70","series-title":"Radiother Oncol","first-page":"54","article-title":"Carbon ion radiation therapy for high-risk meningiomas","volume":"95","author":"Combs SE","year":"2010","unstructured":"Combs SE, Hartmann C, Nikoghosyan A,  Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol. 2010;95(1):54\u201359. doi:10.1016\/j.radonc.2009.12.029"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/61\/3\/article-pE10.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/61\/3\/article-pE10.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/61\/3\/article-pE10.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:01:26Z","timestamp":1788307286000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/61\/3\/article-pE10.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":70,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3171\/2026.6.focus26255","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}